Trusted Resource for Clinical Trials, Protocols & Progress
As decentralized and hybrid clinical trials gain traction, electronic informed consent (eConsent) has become a cornerstone of remote patient onboarding. Traditional paper-based consent processes are ill-suited for remote setups, and regulators have increasingly recognized the importance of digitized alternatives that preserve compliance, clarity, and participant autonomy.
Click to read the full article.
As remote and decentralized trials become increasingly common, traditional methods of presenting informed consent through static documents are no longer sufficient. Multimedia-enabled eConsent tools—featuring videos, interactive graphics, quizzes, and voiceovers—enhance comprehension, especially for diverse and multilingual populations. They also align with regulatory expectations for ensuring patient understanding before enrollment.
Click to read the full article.
The adoption of remote eConsent has transformed how participants engage with clinical trials, particularly in decentralized and hybrid models. With the shift from traditional paper-based consent processes, regulatory authorities have recognized the need to establish clear guidelines for ensuring participant understanding, ethical enrollment, and data integrity in virtual environments.
Click to read the full article.
In decentralized and hybrid clinical trials, remote patient enrollment has become increasingly common. With this shift comes the challenge of verifying a participant’s identity during the electronic informed consent (eConsent) process. Regulatory agencies, including the FDA and EMA, emphasize that the identity of clinical trial subjects must be verified with the same rigor as in-person enrollment, even in remote settings.
Click to read the full article.
The rise of decentralized and hybrid clinical trials has made the electronic informed consent (eConsent) process more critical than ever. However, standalone eConsent platforms create a data silo that limits visibility and auditability. Regulatory agencies, including the FDA and EMA, expect seamless integration of eConsent data with Electronic Data Capture (EDC) systems to ensure traceability, prevent protocol deviations, and facilitate inspection readiness.
Click to read the full article.
As decentralized and hybrid clinical trials become more prevalent, mobile devices are increasingly used as the primary platform for participant engagement. One of the critical components of this shift is the use of mobile apps to deliver and capture informed consent electronically (eConsent). Regulators such as the FDA, EMA, and ICH GCP authors recognize the value of mobile platforms but emphasize that the interfaces must meet rigorous compliance standards.
Click to read the full article.
Remote data collection is a central component of decentralized and hybrid clinical trial models. Patient portals are increasingly used as the interface between trial participants and clinical data capture systems. These portals enable participants to submit electronic diaries, complete questionnaires, and communicate with study personnel. However, their implementation must be meticulously planned to ensure compliance with Good Clinical Practice (GCP) principles, 21 CFR Part 11, GDPR, HIPAA, and other applicable regulatory frameworks.
Click to read the full article.
With the shift towards decentralized clinical trials (DCTs), the use of Internet of Things (IoT) devices and wearable technology has gained widespread acceptance for remote monitoring and real-time data capture. Devices such as smartwatches, biosensors, digital patches, and connected inhalers allow continuous data collection from trial participants outside of traditional clinical settings. However, the integration of these technologies introduces unique compliance risks, especially related to data integrity, validation, patient privacy, and corrective action.
Click to read the full article.
Decentralized and hybrid clinical trial models have introduced new complexities in data capture. With participants reporting data via eConsent platforms, wearable devices, mobile apps, or portals, the risk of missing data has increased. Missing data may arise from technical issues, patient non-compliance, data sync failures, or platform errors. Regardless of the cause, such gaps can pose serious threats to data integrity, endpoint reliability, and regulatory compliance.
Click to read the full article.
Patient engagement is a cornerstone of decentralized and hybrid clinical trials. Real-time patient feedback, especially when gathered through mobile apps, ePRO platforms, and remote portals, plays a vital role in improving protocol adherence, detecting early safety signals, and enhancing the overall trial experience. As the industry moves toward patient-centric models, capturing and acting on feedback becomes a regulatory and operational imperative.
Click to read the full article.
